Phosphogliv URSO (Glycyrrhizic acid, Ursodiol) 50 capsules 35 + 250 mg

Phosphogliv URSO (Glycyrrhizic acid, Ursodiol) 50 capsules 35 + 250 mg

SKU:2120
To favorites
The combined drug Phosphogliv URSO, a hepatoprotective agent, also has a choleretic, cholelitholytic, antioxidant, anti-inflammatory effect, affects fibrogenesis
Active substance:Glycyrrhizic acid, Ursodiol
Pharmacological group:Hepatoprotectors
Formulation:Capsules
Dosage mg:285
In stock
$35
11
Description
Features
Reviews

Instructions for Phosphogliv URSO (Glycyrrhizic acid, Ursodiol) 50 capsules 35 + 250 mg

English Product Name
Phosphogliv Urso

Dosage form
Capsules

Description Phosphogliv URSO:

Capsules hard gelatin, No0, white; contents - white or white powder with a cream tint of color.

1 caps.
ursodeoxycholic acid 250 mg
sodium glycyrrhizinate 35 mg

Excipients:
microcrystalline cellulose M 101 - 30.5 mg,
croscarmellose sodium - 6.6 mg,
hyprolose (hydroxypropyl cellulose) - 3.3 mg,
magnesium stearate - 2.8 mg,
silicon dioxide colloidal (aerosil) - 1.8 mg.

Composition of the capsule shell (body and lid):
titanium dioxide (E 171) - 1.92 mg,
gelatin - 94.08 mg.
ten pieces. - Cellular contour packs (5) - cardboard packs.

pharmachologic effect Phosphogliv URSO:

Combined drug.
It has hepatoprotective, choleretic, cholelitolytic, antioxidant, anti-inflammatory action; affects fibrogenesis.

Ursodeoxycholic acid

Bile acid. Reduces the cholesterol content in bile mainly by dispersing cholesterol and forming a liquid crystalline phase. It affects the enterohepatic circulation of bile salts, reducing the reabsorption in the intestine of endogenous more hydrophobic and potentially toxic compounds. In vitro studies have shown that ursodeoxycholic acid has a direct hepatoprotective effect and reduces the hepatotoxicity of hydrophobic bile salts. It affects immunological reactions, reducing the pathological expression of HLA-antigens of class I on hepatocytes and suppressing the production of cytokines and interleukins.

Testimony Phosphogliv URSO:

  • Non-alcoholic steatohepatitis, 
  • alcoholic liver disease, 
  • chronic hepatitis of various origins, 
  • biliary reflux gastritis,
  • biliary dyskinesia of the biliary tract,
  • dissolution of cholesterol stones of the gallbladder, 
  • primary biliary cirrhosis of the liver in the absence of signs of decompensation, 
  • primary sclerosing cholangitis.

Dosage, Course and Dosage:

Inwards. The dosage regimen is individual, depending on the indications, the patient's age and the clinical situation.

Use in children
The drug is contraindicated for use in children and adolescents under the age of 12 years

  • Nosology Phosphogliv URSO (ICD codes)
  • B18
  • Chronic viral hepatitis
  • K29
  • Gastritis and duodenitis
  • K70
  • Alcoholic liver disease
  • K73
  • Chronic hepatitis not classified under other headings
  • K74.3
  • Primary biliary cirrhosis
  • K76.0
  • Fatty liver (liver degeneration), not classified under other headings
  • K80
  • Cholelithiasis [cholelithiasis] (including hepatic colic)
  • K82.8
  • Other advanced diseases of the gallbladder and cystic duct (including dyskinesia)
  • K83.0
  • Cholangitis
Features
Active substance
Pharmacological group
Formulation
Dosage mg
Pills in 1 package
Country of origin
Brand
Expiration Date
No reviews yet — your comment may be first.
All reviews 0
general rating